All In Biotech

NDA 209604 · Accord Hlthcare

Gemcitabine Hydrochloride

Gemcitabine Hydrochloride · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 3, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,514

702 Phase 3, 512 recruiting

FAERS reports

14,000

13,603 serious, 2,613 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 3, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
4 products under this application
  • GEMCITABINE HYDROCHLORIDE · GEMCITABINE HYDROCHLORIDE 1.5GM/15ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • GEMCITABINE HYDROCHLORIDE · GEMCITABINE HYDROCHLORIDE 200MG/2ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • GEMCITABINE HYDROCHLORIDE · GEMCITABINE HYDROCHLORIDE 2GM/20ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • GEMCITABINE HYDROCHLORIDE · GEMCITABINE HYDROCHLORIDE 1GM/10ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Gemcitabine" as an intervention, any sponsor and status, largest first.

All 3,514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,385
  • myelosuppression1,153
  • malignant neoplasm progression846
  • thrombocytopenia766
  • anaemia679
  • neutropenia668
  • pyrexia667
  • nausea627
  • vomiting534
  • platelet count decreased505
  • diarrhoea498
  • death490

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200514
200631
20071
20084
20095
201089
2011486
2012629
2013482
2014489
2015457
2016534
2017597
2018768
20191,148
20201,112
20211,018
20221,028
20231,189
20241,542
20251,394
2026969

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,445 on PubMed

Sponsor: Accord Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.